Patent intelligence · US
US 10927136
Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators
Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators
Patent details — US 10927136
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 23, 2021
- Expiration
- Feb 18, 2041
- Applicant
- Cyclerion Therapeutics, Inc.
- Claims
- 16
- CPC classes
- A61P, A61P1/16, A61P11/00, A61P11/06
Quick answer
US 10927136 (Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cyclerion Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61P, A61P1/16, A61P11/00, A61P11/06, A61P11/08, A61P13/08
More from Cyclerion Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12247025
Processes for preparation of soluble guanylate cyclase stimulators
granted -
US 11834444
Processes for preparation of soluble guanylate cyclase stimulators
granted -
US 11731977
SGC stimulators
granted -
US 11690828
Treatment of CNS diseases with sGC stimulators
granted -
US 11572358
Solid forms of an sGC stimulator
granted -
US 11466015
Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
granted -
US 11389449
Treatment of metabolic syndrome with an sGC stimulator
granted -
US 11357777
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
granted
Frequently asked questions
What is US patent 10927136?
US 10927136 (Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators) is held by Cyclerion Therapeutics, Inc.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10927136?
Cyclerion Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 10927136 expire?
Our index shows an expiration date of Feb 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.